HERIZON-BTC-01, a pivotal phase IIb, open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in patients with previously treated HER2-amplified and expressing biliary tract cancers, produced positive topline results.
Sarah Bigelow was named executive director of the Clinical Trials Office at the Tulane Cancer Center.
